Client:Chi MedSource:The Independent (Main)Date:20 August 2007Page:33Circulation:255492Size:26cm2AVE:250.12

Citigate Dewe Rogerson

<u>Chi-Med</u> in R&D deal with Eli Lilly

■ Chi-Med, the pharmaceutical business owned by Chinese group Hutchison Whampoa will today announce a big research and development collaboration with US drugs giant Eli Lilly. The AIMlisted group will be eligible for milestone payments of up to \$29m (£14.6m) per drug candidate as well as royalties if the treatments it discovers make it to market. The work will initially be focused on oncology and inflammation.

Coverage is reproduced under licence from the NLA, CLA or other copyright owner. No further copying (including the printing of digital cuttings), digital reproduction or forwarding is permitted except under license from the NLA, http://www.nla.co.uk (for newspapers) CLA, http://www.cla.co.uk (for books & magazines) or other copyright body.